NVNasir Vadia

Nasir Vadia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nasir Vadia has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of polypharmacy among older adults with diabetes: A systematic review and Meta-Analysis

    by Prakasini Satapathy, Abhay M. Gaidhane, Nasir Vadia, Soumya V. Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Muhammed Shabil, Mahendra Singh, Sanjit Sah, Doddolla Lingamaiah, et al.

    Objective Polypharmacy, the concurrent use of five or more medications, is prevalent among older adults with Diabetes, a population at elevated risk for medication-related complications. Complex treatment regimens for Diabetes and its comorbidities exacerbate challenges such as medication non-adherence, drug interactions, adverse events, and increased hospitalization risk. This review aimed to estimate the prevalence of polypharmacy among older adults with Diabetes. Method Following PRISMA 2020 guidelines, we performed a systematic search of PubMed, Embase, and Web of Science. Screened articles using Nested Knowledge software. Eligible studies included those aged 60 years or older with Diabetes, reporting on the prevalence of polypharmacy. Study quality was assessed using a modified Newcastle-Ottawa Scale, and meta-analysis was performed using random-effects models in R software version 4.4.1. Publication bias was indicated by a Doi plot with an LFK index. Results The pooled prevalence of polypharmacy was 59% (95% CI, 48%-70%). Subgroup analyses showed a prevalence of 55% in retrospective studies and 62% in cross-sectional studies. Sensitivity analyses confirmed the stability of the results. Significant geographic variability was noted, with lower prevalence in high-income countries compared to regions in Southern Europe and Asia. Conclusions Polypharmacy is highly prevalent among older adults with Diabetes, with significant variability across study designs and geographic regions. Targeted interventions and further research are essential to address its associated risks and optimize medication management.


  • Association of chemsex and risk of chlamydia, gonorrhoea, and syphilis infections: a systematic review and meta-analysis

    by Prakasini Satapathy, Abhay M. Gaidhane, Nasir Vadia, Soumya V. Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Manpreet Kaur, Ganesh Bushi, Muhammed Shabil, Diptismita Jena, et al.


  • Resveratrol in oral cancer: a systematic review of preclinical studies on its anticancer mechanisms and therapeutic potential

    by Bingru Li, Omer Qutaiba B. Allela, Wadhah Hasan Alkhazali, Nasir Vadia, S. Renuka Jyothi, Rajashree Panigrahi, Ashish Singh Chauhan, Surbhi Singh, Malika Akhrorova, Hayder Naji Sameer, et al.

    Objective Oral cancer remains a major global health challenge due to its aggressive nature, high recurrence rates, and limited treatment options. Resveratrol (RV), a naturally occurring polyphenol, has demonstrated promising anticancer properties in various malignancies, including oral cancer. This systematic review aimed to evaluate preclinical evidence on RV’s therapeutic effects in oral cancer, focusing on its mechanisms of apoptosis induction, metastasis inhibition, autophagy regulation, and immune modulation. Methods A systematic review was conducted following PRISMA guidelines, with a comprehensive search in Google Scholar, PubMed, Embase, Scopus, and Web of Science for preclinical studies published up to March 2, 2025. Both in vitro and in vivo studies investigating RV’s effects on oral cancer were included based on predefined inclusion and exclusion criteria. Data extraction was performed independently by multiple researchers, with discrepancies resolved through consensus. Key mechanisms of RV’s anticancer activity, including apoptosis, metastasis suppression, autophagy, and immune regulation, were analyzed. Results Out of 346 studies screened, 19 (four in vivo and 15 in vitro) met the eligibility criteria. RV exhibited potent anticancer effects in a dose- and time-dependent manner, significantly reducing oral cancer cell viability and tumor growth in animal models. Mechanistically, RV induced apoptosis through caspase-3, -7, and -9 activation and modulation of pro-apoptotic (Bax, Bak) and anti-apoptotic (Bcl-2, Bcl-XL) proteins. RV also inhibited key oncogenic pathways, including Akt/mTOR and JAK2/STAT3, thereby suppressing tumor proliferation and immune evasion. Additionally, RV impaired metastatic progression by downregulating EMT-related transcription factors (TWIST, SLUG, and Zeb1) and reducing angiogenic markers such as VEGF and MMPs. Notably, RV induced autophagy in a dose- and time-dependent manner, as evidenced by increased LC3-II, Beclin1, and p62 expression. In cisplatin-resistant oral cancer models, RV promoted both apoptotic and autophagic cell death, suggesting its potential as an adjuvant therapy. Conclusion This systematic review underscored the potential of RV as a promising anticancer agent for oral cancer. Through apoptosis induction, metastasis suppression, autophagy modulation, and immune regulation, RV demonstrated broad-spectrum anticancer effects. However, its low bioavailability remains a significant challenge. Future research should focus on optimizing drug delivery strategies, such as nanoparticle formulations and combination therapies, to enhance RV’s therapeutic efficacy and facilitate clinical translation.


  • Creatinine as a predictor of proliferative diabetic retinopathy among patients with type 2 diabetes mellitus: a systematic review and meta-analysis

    by Ganesh Bushi, Abhay M. Gaidhane, Nasir Vadia, Soumya V. Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Muhammed Shabil, Anju Rani, Sanjit Sah, Ambanna Yappalparvi, et al.

    Background Proliferative diabetic retinopathy (PDR) is a sight-threatening complication of type 2 diabetes mellitus (T2DM), with limited tools available for early prediction. Serum creatinine, a marker of kidney function, may reflect shared microvascular pathology between diabetic nephropathy and retinopathy. However, its role in predicting PDR remains unclear. This review assessed the association between serum creatinine levels and the presence of PDR among patients with T2DM. Methods This systematic review and meta-analysis followed PRISMA guidelines and was registered in PROSPERO (CRD42024595835). A comprehensive search was conducted in PubMed, Embase, and Web of Science up to October 3, 2024. Observational studies reporting serum creatinine levels in patients with PDR versus non-proliferative diabetic retinopathy (NPDR) or no diabetic retinopathy (non-DR) were included. Standardized mean differences (SMDs) were pooled using a random-effects model. Heterogeneity was assessed with the I2 statistic, and sensitivity analyses, meta-regression, and publication bias assessments were performed. Results Eighteen studies involving 25,034 individuals were included. Serum creatinine levels were significantly higher in patients with PDR compared with non-DR (SMD, 0.97; 95% CI, 0.61–1.33; I2 = 95.7%) and NPDR (SMD, 0.46; 95% CI, 0.15–0.77; I2 = 82.7%). Sensitivity analyses confirmed the robustness of these findings. Meta-regression revealed no significant influence of HbA1c or diabetes duration on effect sizes. The association persisted despite high heterogeneity and potential publication bias. Conclusion Elevated serum creatinine levels are significantly associated with the presence of PDR in patients with T2DM. Although creatinine may serve as a potential biomarker for identifying individuals at risk of PDR progression, further prospective, standardized studies are needed to validate its clinical utility.


  • Open Access

    Prevalence of recurrent nerve injury among esophageal cancer patients undergoing esophagectomy: A systematic review and meta-analysis

    by Prakasini Satapathy, Abhay M. Gaidhane, Nasir Vadia, Soumya V. Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Ganesh Bushi, Mahendra Singh, Sanjit Sah, Awakash Turkar, et al.


  • Open Access

    Exposure to violence and risk of hypertensive disorders in pregnancy: Systematic review and meta-analysis

    by Prakasini Satapathy, Abhay M. Gaidhane, Nasir Vadia, Soumya V. Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Ganesh Bushi, Mahendra Singh, Sanjit Sah, Awakash Turkar, et al.


  • Association of estimated glomerular filtration rate with proliferative diabetic retinopathy: a systematic review and meta-analysis

    by Prakasini Satapathy, Abhay M. Gaidhane, Nasir Vadia, Soumya V. Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Sanjit Sah, Ambana Yappalparvi, S. Govinda Rao, Khang Wen Goh, et al.

    Background Proliferative diabetic retinopathy (PDR) is a serious vision-threatening complication of diabetes. Chronic kidney disease (CKD), measured by estimated glomerular filtration rate (eGFR), shares similar pathophysiological mechanisms with diabetic retinopathy, including inflammation, oxidative stress, and vascular dysfunction. However, the strength of the association between eGFR and PDR remains unclear. This review evaluates the association between reduced eGFR and the risk of PDR in individuals with diabetes. Methods A comprehensive literature search was conducted in PubMed, Embase, and Web of Science, from inception to October 2024. Observational studies reporting both eGFR values and PDR status were included. Study quality was assessed using the Newcastle–Ottawa Scale. Pooled standardized mean differences (SMD) were calculated using a fixed-effects model when heterogeneity was low (I2 ≤ 50%). Subgroup analyses based on eGFR estimation method Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), sensitivity analyses, and meta-regression for diabetes duration and HbA1c were conducted. Publication bias was evaluated using funnel plots and Egger’s test. Results A total of 11 studies were included, comprising 602 patients with PDR and 5,475 individuals without diabetic retinopathy. The pooled SMD for eGFR between PDR and non-PDR groups was − 0.43 (95% CI − 0.52 to − 0.34; P < 0.0001), indicating significantly lower eGFR in PDR patients. Heterogeneity was moderate (I2 = 42.3%). Subgroup analysis showed an SMD of − 0.58 (95% CI − 1.02 to − 0.14; I2 = 0%) using the MDRD formula and − 0.43 (95% CI − 0.58 to − 0.28; I2 = 80.4%) with the CKD-EPI formula. Meta-regression revealed a significant negative association between diabetes duration and PDR proportion (P = 0.0155), but no association with HbA1c (P = 0.7798). The prediction interval ranged from − 0.53 to − 0.33. Funnel plot asymmetry suggested potential publication bias (P < 0.05). Conclusions This systematic review and meta-analysis found a significant association between reduced eGFR and PDR in patients with diabetes, with consistent findings across studies and eGFR estimation methods. Though heterogeneity suggests caution in interpretation. Additional prospective using standardized methodologies are needed to clarify causality and enhance risk prediction.


  • Burden of inguinal, femoral, and abdominal hernias in India: A systematic analysis of prevalence, incidence, mortality, and DALYs from global burden of disease study 1990–2021 with projections to 2031

    by Prakasini Satapathy, Ashutosh Jena, Abhay M. Gaidhane, Nasir Vadia, Soumya V. Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Manpreet Kaur, Ganesh Bushi, Muhammed Shabil, et al.

    Background Hernias are a major health concern in India, with varying incidence and prevalence influenced by socio-demographic factors. Despite global advances in hernia management, regional disparities are evident within India. Method This analysis utilized data from the Global Burden of Disease (GBD) Study 2021 to examine inguinal, femoral, and abdominal hernias across India from 1990 to 2021, categorized by ICD-10 codes. Key metrics analyzed included prevalence, incidence, mortality, and Disability-Adjusted Life Years (DALYs), with age-standardized rates (ASRs). The Estimated Annual Percentage Change (EAPC) for incidence and mortality, Spearman correlation for assessing the relationship between Socio-Demographic Index (SDI) and hernia metrics, and ARIMA models for future trend projections were employed. Result Between 1990 and 2021, the age-standardized incidence rate (ASIR) of hernias in India decreased from 143.85 to 137.05 per 100,000, a reduction of 4.72%, despite a 46% increase in the absolute number of hernia cases due to population growth. Mortality rates significantly declined by 57.05%. DALYs also decreased from 98.01 to 43.51 per 100,000. Projections for 2031 indicate stabilization of incidence rates and an increase in prevalence. Conclusions Significant improvements in hernia management in India have been achieved over three decades, driven by advances in healthcare and socio-demographic progress. However, the rising number of cases and expected increase in prevalence highlight the need for enhanced healthcare strategies and resource allocation to manage the hernia burden effectively.


  • Epidemiology, transmission dynamics, treatment strategies, and future perspectives on Oropouche virus

    by Beema T Yoosuf, Abhay M Gaidhane, Nasir Vadia, Soumya V Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Ganesh Bushi, Anju Rani, Sanjit Sah, Muhammed Shabil, et al.


  • Maternal hypertensive disorders among Individuals of reproductive age (15–49 Years) in South Asia: A global Burden of Disease study (1990–2021) with future Projections

    by Muhammed Shabil, Abhay M Gaidhane, Nasir Vadia, Soumya V Menon, Kattela Chennakesavulu, Rajashree Panigrahi, Ganesh Bushi, Diptismita Jena, Harish Kumar, Anju Rani, et al.